AIM Sale Purchase Of Stock vs Net Income Analysis
| AIM Stock | USD 0.22 0 2.23% |
AIM ImmunoTech financial indicator trend analysis is way more than just evaluating AIM ImmunoTech prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether AIM ImmunoTech is a good investment. Please check the relationship between AIM ImmunoTech Sale Purchase Of Stock and its Net Income accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AIM ImmunoTech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.
Sale Purchase Of Stock vs Net Income
Sale Purchase Of Stock vs Net Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of AIM ImmunoTech Sale Purchase Of Stock account and Net Income. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between AIM ImmunoTech's Sale Purchase Of Stock and Net Income is -0.49. Overlapping area represents the amount of variation of Sale Purchase Of Stock that can explain the historical movement of Net Income in the same time period over historical financial statements of AIM ImmunoTech, assuming nothing else is changed. The correlation between historical values of AIM ImmunoTech's Sale Purchase Of Stock and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Sale Purchase Of Stock of AIM ImmunoTech are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of Sale Purchase Of Stock i.e., AIM ImmunoTech's Sale Purchase Of Stock and Net Income go up and down completely randomly.
Correlation Coefficient | -0.49 |
| Relationship Direction | Negative |
| Relationship Strength | Very Weak |
Sale Purchase Of Stock
Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in AIM ImmunoTech financial statement analysis. It represents the amount of money remaining after all of AIM ImmunoTech operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most indicators from AIM ImmunoTech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into AIM ImmunoTech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AIM ImmunoTech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.At this time, AIM ImmunoTech's Selling General Administrative is very stable compared to the past year. As of the 11th of December 2024, Sales General And Administrative To Revenue is likely to grow to 109.87, while Issuance Of Capital Stock is likely to drop about 68.4 K.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 67K | 478K | 549.7K | 281.1K | Research Development | 7.7M | 7.0M | 10.9M | 6.9M |
AIM ImmunoTech fundamental ratios Correlations
Click cells to compare fundamentals
AIM ImmunoTech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
AIM ImmunoTech fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 13.8M | 20.2M | 64.6M | 40.5M | 19.4M | 29.4M | |
| Short Long Term Debt Total | 6.4M | 2.3M | 149K | 837K | 718K | 682.1K | |
| Other Current Liab | 214K | 672K | 438K | 806K | 1.8M | 1.3M | |
| Total Current Liabilities | 1.1M | 1.1M | 673K | 1.4M | 8.7M | 9.1M | |
| Total Stockholder Equity | 12.9M | 61.3M | 56.9M | 38.5M | 10.2M | 9.7M | |
| Property Plant And Equipment Net | 7.3M | 6.7M | 4.2M | 1.0M | 824K | 782.8K | |
| Net Debt | 4.9M | (36.2M) | (31.9M) | (26.2M) | (4.7M) | (5.0M) | |
| Retained Earnings | (328.1M) | (342.0M) | (361.1M) | (380.5M) | (409.5M) | (389.0M) | |
| Accounts Payable | 472K | 383K | 198K | 377K | 6.4M | 6.8M | |
| Cash | 1.5M | 38.5M | 32.1M | 27.1M | 5.4M | 10.3M | |
| Non Current Assets Total | 9.8M | 24.3M | 7.5M | 4.2M | 4.8M | 8.5M | |
| Cash And Short Term Investments | 8.8M | 39.0M | 48.3M | 34.2M | 13.1M | 19.4M | |
| Common Stock Shares Outstanding | 3.6M | 31.8M | 47.3M | 48.0M | 48.6M | 51.0M | |
| Liabilities And Stockholders Equity | 13.8M | 20.2M | 64.6M | 40.5M | 19.4M | 29.4M | |
| Other Current Assets | 848K | 184K | 304K | 455K | 604K | 528.6K | |
| Other Stockholder Equity | 340.2M | 402.5M | 417.2M | 418.3M | 419.0M | 251.9M | |
| Total Liab | 7.3M | 3.3M | 820K | 2.0M | 9.1M | 9.6M | |
| Total Current Assets | 10.4M | 40.3M | 50.2M | 36.3M | 14.6M | 20.9M | |
| Short Term Debt | 252K | 47K | 37K | 178K | 446K | 423.7K | |
| Intangible Assets | 1.2M | 1.5M | 2.0M | 1.9M | 2.3M | 1.3M | |
| Non Currrent Assets Other | 1.4M | (46.3M) | 1.3M | 1.2M | 1.7M | 1.8M | |
| Net Receivables | 820K | 1.1M | 1.6M | 1.7M | 1.2M | 747.1K | |
| Short Term Investments | 7.3M | 501K | 16.2M | 7.1M | 7.6M | 11.5M | |
| Common Stock | 33K | 49K | 10K | 42K | 48K | 89.5K | |
| Non Current Liabilities Total | 6.2M | 2.2M | 147K | 659K | 495K | 470.3K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in AIM ImmunoTech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AIM ImmunoTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.47) | Revenue Per Share 0.004 | Quarterly Revenue Growth 0.19 | Return On Assets (0.80) | Return On Equity (1.55) |
The market value of AIM ImmunoTech is measured differently than its book value, which is the value of AIM that is recorded on the company's balance sheet. Investors also form their own opinion of AIM ImmunoTech's value that differs from its market value or its book value, called intrinsic value, which is AIM ImmunoTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AIM ImmunoTech's market value can be influenced by many factors that don't directly affect AIM ImmunoTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AIM ImmunoTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if AIM ImmunoTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.